v3.26.1
COMMITMENTS AND CONTINGENCIES (Details)
 12 Months Ended
Apr. 30, 2026
USD ($)
Pre-IND Meeting [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due date Pre-IND Meeting - Completed September 2019 [1]
IND application filing [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 65,000
Due date IND application filing - Completed June 2021 [1]
Upon first dosing of patient in a clinical trial [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 190,000
Due date Upon first dosing of patient in a clinical trial - Completed December 2021 [1]
Upon completion of first clinical trial [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 500,000
Due date Upon completion of first clinical trial - Completed March 2022 [1]
Upon first patient treated in a Phase III clinical trial [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,250,000
Due date Upon first patient treated in a Phase III clinical trial
Upon first patient treated in a Phase III clinical trial [Member] | Additional A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 2,000,000
Due date Upon first patient treated in a Phase III clinical trial
Upon FDA NDA approval [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 10,000,000
Due date Upon FDA NDA approval
Upon IND application [Member] | ALZN002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due date Upon IND application - Completed January 2022 [2]
Upon first dosing of patient in first Phase I clinical trial [Member] | ALZN002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due date Upon first dosing of patient in first Phase I clinical trial
Upon completion of first Phase IIB clinical triall [Member] | ALZN002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 500,000
Due date Upon completion of first Phase IIB clinical trial
Upon first patient treated in a Phase III clinical trial [Member] | ALZN002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,000,000
Due date Upon first patient treated in a Phase III clinical trial
Upon first commercial sale [Member] | ALZN002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 10,000,000
Due date Upon first commercial sale
First commercial sale [Member] | Additional A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 16,000,000
Due date First commercial sale
[1] Milestone met and completed
[2] Milestone met and completed